Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Chelation
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Nutritional advantages and issues === Chelation in the intestinal tract is a cause of numerous interactions between drugs and metal ions (also known as "[[Dietary mineral|minerals]]" in nutrition). As examples, [[antibiotic]] [[medication|drug]]s of the [[tetracycline]] and [[Quinolone antibiotic|quinolone]] families are chelators of [[iron|Fe]]<sup>2+</sup>, [[Calcium|Ca]]<sup>2+</sup>, and [[Magnesium|Mg]]<sup>2+</sup> ions.<ref>{{cite journal |vauthors=Campbell NR, Hasinoff BB |title=Iron supplements: a common cause of drug interactions |journal=British Journal of Clinical Pharmacology |volume=31 |issue=3 |pages=251β5 |date=March 1991 |pmid=2054263 |pmc=1368348 |doi=10.1111/j.1365-2125.1991.tb05525.x}}</ref><ref>{{cite journal |vauthors=Lomaestro BM, Bailie GR |title=Absorption interactions with fluoroquinolones. 1995 update |journal=Drug Safety |volume=12 |issue=5 |pages=314β33 |date=May 1995 |pmid=7669261 |doi=10.2165/00002018-199512050-00004 |s2cid=2006138}}</ref> EDTA, which binds to calcium, is used to alleviate the [[hypercalcemia]] that often results from [[band keratopathy]]. The calcium may then be removed from the [[cornea]], allowing for some increase in clarity of vision for the patient.<ref>{{Cite journal |last=Najjar |first=Dany M. |last2=Cohen |first2=Elisabeth J. |last3=Rapuano |first3=Christopher J. |last4=Laibson |first4=Peter R. |date=June 2004 |title=EDTA chelation for calcific band keratopathy: results and long-term follow-up |url=https://pubmed.ncbi.nlm.nih.gov/15183790/ |journal=American Journal of Ophthalmology |volume=137 |issue=6 |pages=1056β1064 |doi=10.1016/j.ajo.2004.01.036 |issn=0002-9394 |pmid=15183790}}</ref><ref>{{Cite journal |last=Al-Hity |first=A |last2=Ramaesh |first2=K |last3=Lockington |first3=D |date=December 1, 2017 |title=EDTA chelation for symptomatic band keratopathy: results and recurrence |url=https://pmc.ncbi.nlm.nih.gov/articles/PMC5770724/ |journal=Eye |language=en |volume=32 |issue=1 |pages=26β31 |doi=10.1038/eye.2017.264 |issn=0950-222X |archive-url=http://web.archive.org/web/20250202182230/https://pmc.ncbi.nlm.nih.gov/articles/PMC5770724/ |archive-date=February 2, 2025|pmc=5770724}}</ref> [[Homogeneous catalyst]]s are often chelated complexes. A representative example is the use of [[BINAP]] (a bidentate [[phosphine]]) in [[Noyori asymmetric hydrogenation]] and asymmetric isomerization. The latter has the practical use of manufacture of synthetic [[Menthol|(β)-menthol]].
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)